WT1-specific TCRs directed against newly identified peptides install antitumor reactivity against acute myeloid leukemia and ovarian carcinoma

BACKGROUND: Transcription factor Wilms’ tumor gene 1 (WT1) is an ideal tumor target based on its expression in a wide range of tumors, low-level expression in normal tissues and promoting role in cancer progression. In clinical trials, WT1 is targeted using peptide-based or dendritic cell-based vacc...

Descripción completa

Detalles Bibliográficos
Autores principales: van Amerongen, Rosa A, Hagedoorn, Renate S, Remst, Dennis F G, Assendelft, Danique C, van der Steen, Dirk M, Wouters, Anne K, van de Meent, Marian, Kester, Michel G D, de Ru, Arnoud H, Griffioen, Marieke, van Veelen, Peter A, Falkenburg, J H Frederik, Heemskerk, Mirjam H M
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2022
Materias:
Immune Cell Therapies and Immune Cell Engineering
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214430/
https://www.ncbi.nlm.nih.gov/pubmed/35728869
http://dx.doi.org/10.1136/jitc-2021-004409

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9214430/
https://www.ncbi.nlm.nih.gov/pubmed/35728869
http://dx.doi.org/10.1136/jitc-2021-004409

Ejemplares similares